Genes and Patents: Evolution; Controversies and Perspectives
|出版商||Frost & Sullivan||商品編碼||307110|
|出版日期||內容資訊||英文 56 Pages
|遺傳基因與專利:演進;議論及展望 Genes and Patents: Evolution; Controversies and Perspectives|
|出版日期: 2014年06月30日||內容資訊: 英文 56 Pages||
本報告提供遺傳基因專利領域相關研究，遺傳基因專利的優點，歷史，問題及生命倫理，美國的Association For Molecular Pathology v. Myriad Genetics 事件和美國最高法院的判斷，Myriad Ruling的影響等相關詳細內容。
Who owns our genes?
Genes are the constituent elements of a human body. Genetic research has been carried out to find answers to several questions pertaining to diseases, drug discovery, diagnostics and therapeutics. It is an expensive mode of research and development. As a result, many researchers and developers see the need to secure intellectual property protection by means of patents. This not only secures their expensive invention from being duplicated elsewhere but also provides collateral for funding. But genetic patenting has been in news for quite some time. For many, it is difficult to fathom how a third party can claim ownership over ones genes. Moreover, patenting restricts access to knowledge which in turn provides a setback to the research community. In the light of the above mentioned, the United States Supreme Court deliberated on the celebrated case of Association for Molecular Pathology v. Myriad Genetics. The decision changed to quite an extent the patent eligibility requirements for a naturally occurring gene. It left several previously granted patents vulnerable to be invalidated. The United States Patent and Trademarks Office laid down guidelines for examination of such patent applications, post this decision. The research service highlights such details in the field of gene patenting.